60 research outputs found

    Effect of ripening on physico-chemical properties and bioactive compounds in papaya pulp, skin and seeds

    Get PDF
    Byproducts generated by the food industry represent an alternative to obtain functional ingredients. Byproducts of tropical fruits, such as papaya skin and seeds, represent a source of bioactive compounds (BC), which could change during fruit ripening. Effect of ripening stage (RS) on BC content and antioxidant properties of edible pulp, skin and seeds of papaya cv. Maradol was determined. Papaya skin showed significantly higher ascorbic acid (~250 mg AAE/100 g) content than seeds (~20 mg/100 g), while pulp had the highest values (~600 mg/100 g). However, papaya skin presented higher total phenolic content (~560 mg GAE/100 g) and flavonoids (~1000 mg QE/100 g) than pulp and seeds. Also, papaya skin showed the highest values followed by pulp and seeds with TEAC, FRAP and DPPH. Papaya skin had higher carotenoids and α-tocopherol (~1500 µg/100 g and ~4000 µg/100 g, respectively) content than pulp and seeds. BC content in each byproduct varied in all RS. Therefore, among the papaya byproducts, skin represents a good source of BC with good antioxidant properties, which may be used to extract them for its incorporation in functional foods depending on RS

    Meta-analysis on the effect of the N363S polymorphism of the glucocorticoid receptor gene (GRL) on human obesity

    Get PDF
    BACKGROUND: Since both excess glucocorticoid secretion and central obesity are clinical features of some obese patients, it is worthwhile to study a possible association of glucocorticoid receptor gene (GRL) variants with obesity. Previous studies have linked the N363S variant of the GRL gene to increased glucocorticoid effects such as higher body fat, a lower lean-body mass and a larger insulin response to dexamethasone. However, contradictory findings have been also reported about the association between this variant and obesity phenotypes. Individual studies may lack statistical power which may result in disparate results. This limitation can be overcome using meta-analytic techniques. METHODS: We conducted a meta-analysis to assess the association between the N363S polymorphism of the GRL gene and obesity risk. In addition to published research, we included also our own unpublished data -three novel case-control studies- in the meta-analysis The new case-control studies were conducted in German and Spanish children, adolescents and adults (total number of subjects: 1,117). Genotype was assessed by PCR-RFLP (Tsp509I). The final formal meta-analysis included a total number of 5,909 individuals. RESULTS: The meta-analysis revealed a higher body mass index (BMI) with an overall estimation of +0.18 kg/m(2 )(95% CI: +0.004 to +0.35) for homo-/heterozygous carriers of the 363S allele of the GRL gene in comparison to non-carriers. Moreover, differences in pooled BMI were statistically significant and positive when considering one-group studies from the literature in which participants had a BMI below 27 kg/m(2 )(+ 0.41 kg/m(2 )[95% CI +0.17 to +0.66]), but the differences in BMI were negative when only our novel data from younger (aged under 45) and normal weight subjects were pooled together (-0.50 kg/m(2 )[95% CI -0.84 to -0.17]). The overall risk for obesity for homo-/heterozygous carriers of the 363S allele was not statistically significant in the meta-analysis (pooled OR = 1.02; 95% CI: 0.56–1.87). CONCLUSION: Although certain genotypic effects could be population-specific, we conclude that there is no compelling evidence that the N363S polymorphism of the GRL gene is associated with either average BMI or obesity risk

    Soluciones creativas de intervención

    Get PDF
    En este proyecto se trabajó con empresas socialmente responsables en la creación de vínculos con comunidades, organización y otros ámbitos de la sociedad para mejorar su entorno. Esto se logró a través de la creación de estrategias de comunicación e intervención social, con lo cual la empresa logra obtener un beneficio de posicionamiento y, a la vez, produce un beneficio social tangible

    Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

    Get PDF
    Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

    Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

    Get PDF
    Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat

    Piezoelectric materials as driving element in accelerometers

    Get PDF
    [ES] Los materiales cerámicos piezoeléctricos presentan un número importante y en continuo aumento de aplicaciones. Entre éstas su utilización como elementos activos en el diseño de acelerómetros posibilita el control de vibraciones en la industria del transporte, aerospacial, robótica e ingeniería civil entre otras. Entre los múltiples diseños como material compuesto destaca, gracias a sus elevados coeficientes de carga efectivos, el denominado tipo címbalo. En este trabajo se comprueba que modificando la geometría y el tamaño de las cápsulas se optimiza el comportamiento del sensor. Concretamente una disminución en el tamaño de las cápsulas se traduce en un aumento de la sensibilidad del acelerómetro. También se muestran los espectros de impedancia y se comparan distintas propiedades como son la frecuencia de resonancia, coeficiente de acoplo electromecánico y tiempo mínimo de respuesta.[EN] Piezoelectric ceramic materials have an important number of applications that is continuing increasing. One of these applications is as driving element in the design of an accelerometer. They may be used in monitoring vibration for the automobile and aeroespacial industries and robotic or civil engineering. The cymbal transducer is a good candidate for accelerometer applications due to its high effective piezoelectric charge coefficients. In this work it is shown that changes in the geometry and size of the caps improve the performance of the sensor. The sensitivity of the cymbal accelerometer increases with decreasing cap size. The mechanical vibration response of the cymbal is studied and different properties, like resonant frequency, electromechanical coupling coefficient, and fastest response time are compared.Los autores agradecen el apoyo financiero para la realización de este trabajo. (EUREKA 2309 FACTORY – PAMIS y CICYT-TAP99-1244-CO2-01 (ICARO)).Peer reviewe
    corecore